FindMyKOL
Clinical trialNCT00005964CompletedPhase 2Interventional

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00005964 is a phase 2 interventional trial sponsored by Alliance for Clinical Trials in Oncology. As of 21 Nov 2026, it is completed. It studies Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim and 2 more drugs in Lymphoma. The registry lists an enrollment of 59 participants at 47 sites in 1 country. The registry lists a start date of 31 May 2000 and a primary completion date of 31 Mar 2006. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00005964
FieldValue
Registry IDNCT00005964
StatusCompleted
PhasePhase 2
Study typeInterventional trial
Lead sponsorAlliance for Clinical Trials in Oncology
Enrollment59
Registered sites47
Countries1
ConditionsLymphoma
DrugsCyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Prednisone and Vincristine
Start31 May 2000
Primary completion31 Mar 2006
Study completion31 Mar 2006
Last update posted13 Jul 2016

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating aggressive non-Hodgkin's lymphoma. PURPOSE: Randomized phase II trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have previously untreated aggressive stage II, stage III, or stage IV non-Hodgkin's lymphoma.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

47 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Alabama, United States1 site
  • Veterans Affairs Medical Center - Birmingham

    Birmingham

California, United States3 sites
  • University of California San Diego Cancer Center

    La Jolla

  • Ucsf Cancer Center and Cancer Research Institute

    San Francisco

  • Veterans Affairs Medical Center - San Francisco

    San Francisco

Delaware, United States1 site
  • Ccop - Christiana Care Health Services

    Wilmington

District of Columbia, United States2 sites
  • Lombardi Cancer Center

    Washington D.C.

  • Walter Reed Army Medical Center

    Washington D.C.

Florida, United States1 site
  • Ccop - Mount Sinai Medical Center

    Miami Beach

Illinois, United States2 sites
  • University of Chicago Cancer Research Center

    Chicago

  • Veterans Affairs Medical Center - Chicago (westside Hospital)

    Chicago

Iowa, United States1 site
  • Holden Comprehensive Cancer Center at the University of Iowa

    Iowa City

Maine, United States1 site
  • Veterans Affairs Medical Center - Togus

    Togus

Maryland, United States1 site
  • Marlene & Stewart Greenebaum Cancer Center, University of Maryland

    Baltimore

Massachusetts, United States2 sites
  • Dana-Farber Cancer Institute

    Boston

  • University of Massachusetts Memorial Medical Center

    Worcester

Minnesota, United States2 sites
  • University of Minnesota Cancer Center

    Minneapolis

  • Veterans Affairs Medical Center - Minneapolis

    Minneapolis

Missouri, United States3 sites
  • Ellis Fischel Cancer Center - Columbia

    Columbia

  • Veterans Affairs Medical Center - Columbia (truman Memorial)

    Columbia

  • Barnes-Jewish Hospital

    St Louis

Nebraska, United States1 site
  • University of Nebraska Medical Center

    Omaha

Nevada, United States1 site
  • Ccop - Southern Nevada Cancer Research Foundation

    Las Vegas

New Hampshire, United States1 site
  • Norris Cotton Cancer Center

    Lebanon

New York, United States10 sites
  • Roswell Park Cancer Institute

    Buffalo

  • Veterans Affairs Medical Center - Buffalo

    Buffalo

  • Ccop - North Shore University Hospital

    Manhasset

  • North Shore University Hospital

    Manhasset

  • Memorial Sloan-Kettering Cancer Center

    New York

  • Mount Sinai Medical Center, Ny

    New York

  • New York Presbyterian Hospital - Cornell Campus

    New York

  • Ccop - Syracuse Hematology-Oncology Associates of Central New York, P.C.

    Syracuse

  • State University of New York - Upstate Medical University

    Syracuse

  • Veterans Affairs Medical Center - Syracuse

    Syracuse

North Carolina, United States5 sites
  • Lineberger Comprehensive Cancer Center, Unc

    Chapel Hill

  • Duke Comprehensive Cancer Center

    Durham

  • Veterans Affairs Medical Center - Durham

    Durham

  • Ccop - Southeast Cancer Control Consortium

    Winston-Salem

  • Comprehensive Cancer Center at Wake Forest University

    Winston-Salem

Ohio, United States1 site
  • Arthur G. James Cancer Hospital - Ohio State University

    Columbus

Rhode Island, United States1 site
  • Rhode Island Hospital

    Providence

Tennessee, United States2 sites
  • University of Tennessee, Memphis Cancer Center

    Memphis

  • Veterans Affairs Medical Center - Memphis

    Memphis

Vermont, United States3 sites
  • Ccop - Southwestern Vermont Regional Cancer Center

    Bennington

  • Vermont Cancer Center

    Burlington

  • Veterans Affairs Medical Center - White River Junction

    White River Junction

Virginia, United States2 sites
  • Mbccop - Massey Cancer Center

    Richmond

  • Veterans Affairs Medical Center - Richmond

    Richmond

United States, by state

AlaskaAKMaine: 1 siteME1Vermont: 3 sitesVT3New Hampshire: 1 siteNH1WashingtonWAMontanaMTNorth DakotaNDMinnesota: 2 sitesMN2WisconsinWIMichiganMINew York: 10 sitesNY10Massachusetts: 2 sitesMA2Rhode Island: 1 siteRI1OregonORIdahoIDSouth DakotaSDIowa: 1 siteIA1Illinois: 2 sitesIL2IndianaINOhio: 1 siteOH1PennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 3 sitesCA3Nevada: 1 siteNV1WyomingWYNebraska: 1 siteNE1Missouri: 3 sitesMO3KentuckyKYWest VirginiaWVVirginia: 2 sitesVA2Maryland: 1 siteMD1Delaware: 1 siteDE1ArizonaAZUtahUTColoradoCOKansasKSArkansasARTennessee: 2 sitesTN2North Carolina: 5 sitesNC5South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabama: 1 siteAL1GeorgiaGAHawaiiHITexasTXFlorida: 1 siteFL1District of Columbia: 2 sitesDC2
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CyclophosphamideDoxorubicinEtoposideFilgrastimPrednisoneVincristine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00005964

Each answer restates registry values shown on this page.

What is NCT00005964?

NCT00005964 is a phase 2 interventional trial sponsored by Alliance for Clinical Trials in Oncology. It studies Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim and 2 more drugs in Lymphoma.

Who leads NCT00005964?

The registry names Andrew Zelenetz, MD, PhD (study chair, Memorial Sloan Kettering Cancer Center) as the overall official.

Where does NCT00005964 run?

The registry lists 47 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00005964 study?

The registered drug and biological interventions are Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Prednisone and Vincristine.

When did NCT00005964 end?

The registry lists a primary completion date of 31 Mar 2006 and a study completion date of 31 Mar 2006. The sponsor last updated the record on 13 Jul 2016.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.